Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase 2/3 next year in neurogenic detrusor overactivity.
Philippe Chambon, Cyllene Therapeutics CEO
July 7, 2026 01:30 AM EDT
FinancingStartupsCell/Gene Tx
French gene therapy biotech gets €33M to follow Krystal's blueprint
Kyle LaHucik
Novartis acquires British start-up Myricx Bio
Gene editing developer Scribe plots an IPO
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C
FDA deepens Vertex's Casgevy label, opening treatment for patients as young as 2
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator.
Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the…
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans…
